VRNA - Sanofi and Regeneron's Dupixent set for large gains with likely COPD approval
2024-03-31 21:35:02 ET
More on Regeneron, Sanofi
- Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate
- Sanofi: My Top Pick In Big Pharma
- Regeneron Pharmaceuticals, Inc. (REGN) Leerink Partners Global Biopharma Conference (Transcript)
- U.S. CDC warns bacteria causing meningitis are on the rise
- Japan approves AstraZeneca-Sanofi drug for prevention of RSV disease in infants